Management of Recurrent C Difficile Infections in the Future

Key Takeaways

• Vowst restores gut microbiome balance using live biotherapeutic products, differing from traditional antibiotic treatments for C. difficile infections.
• Clinical trials showed Vowst significantly reduces recurrence rates, leading to FDA approval for recurrent C. difficile infection.
• Target patients include those with multiple C. difficile recurrences, especially those unresponsive to standard antibiotic therapies.